ASCO 2025 | Novel treatments for advanced melanoma patients who have failed initial therapy
Omid Hamid
• 1 Jun 2025
Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, comments on the need for predictive and prognostic markers to improve outcomes for patients with metastatic advanced melanoma, particularly those who have exhausted checkpoint inhibition. Dr Hamid highlights the potential of novel therapies, including adoptive T cell therapies, bispecifics, and NK cell checkpoint inhibitors, which are showing promising response rates and durability in clinical trials. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
